Symrise Ag · XETR:SY1
Symrise — Symrise Ag Ord — H1 2025 Earnings Presentation
27 slides from Symrise's earnings presentation, Jul 30, 2025
Slide 1: Financial Results H1 2025
Financial Results H1 2025 — Dr. Jean-Yves Parisot (CEO), Olaf Klinger (CFO) 30 July 2025
Slide 2: Agenda
Agenda Overview — 1 H1 2025 2 H1 2025 3 Executing 4 Full Year 2025 At a Glance Financial ONE SYM Outlook Dr. Jean-Yves Parisot, CEO Performance Transformation Olaf Klinger, CFO 2
Slide 3: H1 2025 At a Glance
1 H1 2025 At a Glance 3
Slide 4: Key Messages
1 H1 2025 At a Glance Key Messages — Achieved organic sales growth of 3.1%, EBITDA margin of 21.7%, an increase of 1 100 basis points, and 12% EPS growth year-on-year Entering next phase of ONE SYM Transformation; focus now on Activation Phase 2 to drive profitable growth, operational excellence, an
Slide 5: Adding New Leadership To Drive Results, Deepen Bench Strength
1 H1 2025 At a Glance Adding New Leadership To Drive Results, Deepen Bench Strength — Michael Friede appointed President of Scent & Care New Leaders appointed to key roles • Most recently CEO of Brenntag Specialties • Infusing new leadership to oversee key areas of at Brenntag SE, Essen. transformat
Slide 6: Performance Highlights
1 H1 2025 At a Glance Performance Highlights — Sales Net Income 2 Cost savings and efficiency €2,554m €268m €20m Executing our Profitable Growth +3.1% organic growth -0.5% in reporting currency +12.0% vs. H1 2024 Earnings per share €1.92 realized in H1 2025; additional €20m expected for H2 Strategy
Slide 7: Sales by Segment H1 2025
1 H1 2025 At a Glance Sales by Segment H1 2025 Both Segments with organic volume growth — Taste, Nutrition & Health in €m / organic growth in % Scent & Care in €m / organic growth in % (61% of H1 2025 sales1) (39% of H1 2025 sales1) +3.3% +2.9% Industry-leading growth in Food and Beverages driven by
Slide 8: Sales by Region in H1 2025
1 H1 2025 At a Glance Sales by Region in H1 2025 Double-digit organic growth in Latin America — Organic growth by region Sales by region % of revenue % of global sales North €536m €629m America Asia/Pacific 21% 25% -1.4% +3.2% APAC NA EAME +3.3% Latin €1,048m €341m America 41% 13% +10.6% EAME LATAM
Slide 9: Financial Performance
2 04 H1 2025 Financial Performance XXXXX 9 9
Slide 10: Group: H1 2025
2 H1 2025 Financial Performance Group: H1 2025 Strong performance as we navigate increasingly dynamic demand environment — Sales: H1 2025 Sales: Q2 2025 In €m In €m +3.1% -0.4% -3.2% -0.5% +2.0% 0.0% -4.9% -2.9% -10 1,274 26 0 80 -63 2,565 2,554 1,237 -81 H1 2024 Organic Portfolio FX H1 2025 Q2 2024
Slide 11: Segment: Taste, Nutrition & Health
2 H1 2025 Financial Performance Segment: Taste, Nutrition & Health Healthy growth and strong profitability P&L (Condensed) — In €m Sales: H1 2025 in € million H1 2024 H1 2025 Change in % In €m EBITDA 347.6 364.0 4.7 EBITDA margin in % 22.1 23.3 120 bps +3.3% -0.7% -3.1% EBIT 228.6 260.3 13.9 EBIT ma
Slide 12: Segment: Scent & Care
2 H1 2025 Financial Performance Segment: Scent & Care Single-digit growth with strength in Fragrance P&L (Condensed) — In €m Sales: H1 2025 in € million H1 2024 H1 2025 Change in % In €m EBITDA 182.1 189.6 4.1 EBITDA margin in % 18.3 19.2 90 bps EBIT 137.1 142.6 4.0 +2.9% 0.0% -3.3% EBIT margin in %
Slide 13: Group Profitability
2 H1 2025 Financial Performance Group Profitability EBITDA up 100bps to 21.7% — All comparisons are versus prior year period unless otherwise noted Change Double-digit growth of gross profit, EBITDA margin in € million H1 2024 H1 2025 in %/bps and EBIT Sales 2,565 2,554 -0.5 Gross profit 998 1,057 6
Slide 14: Business Free Cash Flow
2 H1 2025 Financial Performance Business Free Cash Flow Reflects improvements in EBITDA and working capital — BFCF (€m) BFCF (as a % of sales) 681 13,6% 11,7% 553 8,8% 8,8% 301 6,5% 226 226 4,6% 4,4% 104 106 1 1 2 2022 2023 2 2024 2025 2022 2023 2024 2025 H1 FY H1 FY • BFCF of €226m flat year-on-yea
Slide 15: Balance Sheet and Net Debt
2 H1 2025 Financial Performance Balance Sheet and Net Debt Reduction of net debt incl. pensions leads to leverage of 2.4x EBITDA — Balance sheet Highlights FY 2024 H1 2025 Cash and Cash Equivalents €710m €370m Equity ratio1 maintained at a healthy level at 48.3% (2024: 48.3%) Equity ratio1 48.3% 48.
Slide 16: Executing ONE SYM Transformation
3 Executing ONE SYM Transformation 16
Slide 17: In the Early Phases of Our Multi-year ONE SYM Transformation
3 Executing ONE SYM Transformation In the Early Phases of Our Multi-year ONE SYM Transformation Executing ONE Symrise strategy to drive profitable growth: delivering results, seeing momentum — ONE SYM Transformation ONE Symrise Strategy Organization-wide Harnessing and amplifying the potential chang
Slide 18: ONE SYM Transformation: Our Ambition to Be Unique
3 Executing ONE SYM Transformation ONE SYM Transformation Embarked on this journey to take the best of Symrise and transform into a company that generates — durable profitable growth, strong free cash flow, and compounding returns OUR AMBITION TO BE UNIQUE Phase 1: April 2024 – Q1 2025 Phase 2: Q2 2
Slide 19: ONE Symrise Strategy
3 Executing ONE SYM Transformation ONE Symrise Strategy Unleashing the full potential of ONE Symrise — • Proactive portfolio management 1 PORTFOLIO • Global reach with local focus ENABLERS • Niche player in high-quality industry People and • Deeper customer focus Values 2 GROWTH • Innovation leverag
Slide 20: Portfolio
3 Executing ONE SYM Transformation Portfolio Proactively managing portfolio with a focus on profitable growth; acting decisively — Capital Markets Day Nov. 2024 Announcing Strategic Alternatives for Terpenes Ingredients Business Announced portfolio management as a • April 2025: Announced strategic o
Slide 21: Growth
3 Executing ONE SYM Transformation Growth Sharpening customer value-added delivery through differentiated innovation — New launches Notable Recognitions Scent & Care Taste, Nutrition & Health Awards SymLash® Xtreme (Q2) Probi: Clinically proven Symrise receives Unilever’s Patented lipopeptide- bioti
Slide 22: Efficiency
3 Executing ONE SYM Transformation Efficiency Focused on delivering cost savings; recycling portion of savings to strategic investments — Priority Focus Areas Sourcing & Procurement • Key raw materials (e.g., citrus) evaluation €20m Measures aimed • New global sourcing approach for flavoring materia
Slide 23: Full Year 2025 Outlook
4 Full Year 2025 Outlook 23
Slide 24: Full Year Outlook 2025
4 Full Year 2025 Outlook Full Year Outlook 2025 Updating to reflect current global demand environment and execution — of ONE Symrise Strategy 2025 Outlook 2025 Outlook 2025 – 2028 • Current global demand environment more As of Jan 30, 2025 As of July 30, 2025 Targets1 challenging than expected • Hea
Slide 25: Closing Remarks
Closing Remarks ONE SYM Transformation underway; organization mobilized as we enter Activation phase — 1 2 3 Focus on what is within Identified an additional Energized Symrise our control; executing our €40m cost savings in 2025 organization with ~13,000 ONE Symrise strategy with with €20m already r
Slide 26: Symrise always inspiring more
ry symrise always inspiring more
Slide 27: Symrise AG Contact
Symrise AG — Financial calendar 2025 Contact 28 October Symrise AG 9M 2025 Trading statement Muehlenfeldstraße 1 37603 Holzminden, Germany René Weinberg Investor Relations rene.weinberg@symrise.com Bernhard Kott Corporate Communications bernhard.kott@symrise.com This document contains forward-lookin